Last 7 days
-12.7%
Last 30 days
-17.8%
Last 90 days
-5.6%
Trailing 12 Months
-65.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 124.2B | 26.3B | -2.34% | 1.62% | 18.96 | 4.72 | 1.32% | 11.18% |
GILD | 98.0B | 27.3B | -7.18% | 37.83% | 21.33 | 3.59 | -0.09% | -26.23% |
MRNA | 57.1B | 19.3B | -7.28% | -16.95% | 6.83 | 2.97 | 4.29% | -31.47% |
BIIB | 38.1B | 10.2B | -3.01% | 25.82% | 12.5 | 3.74 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.2B | 1.5B | -6.54% | 2.94% | 59.61 | 6.19 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -20.63% | -31.77% | -9.51 | 28.59 | 122.90% | -12.19% |
BEAM | 2.2B | 60.9M | -22.54% | -46.32% | -7.52 | 35.66 | 17.51% | 22.00% |
BBIO | 1.9B | 107.9M | 7.80% | 19.42% | -3.99 | 17.93 | 54.84% | 17.36% |
SMALL-CAP | ||||||||
RCUS | 1.2B | 112.0M | -12.49% | -50.70% | -4.44 | 10.58 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -19.12% | 19.58% | -7.01 | 156.87 | 131.81% | -45.39% |
IOVA | 1.1B | - | -17.78% | -65.10% | -2.74 | - | - | -15.67% |
NVAX | 499.9M | 2.0B | -38.13% | -92.75% | -0.76 | 0.25 | 72.89% | 62.27% |
VXRT | 98.0M | 107.0K | -22.42% | -85.54% | -0.91 | 915.57 | -88.00% | -52.91% |
IBIO | 26.6M | - | 29.52% | -80.89% | -0.33 | 3.21 | 0.51% | -185.61% |
XBIO | 6.0M | 1.6M | -24.22% | -53.86% | -0.87 | 3.87 | 165.64% | -38.13% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Revenue | NaN% | |||||
Interest Expenses | - | 0.00 | - | - | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 21.6% | 664 | 546 | 611 | 701 | 777 |
Current Assets | 29.5% | 479 | 370 | 432 | 490 | 508 |
Cash Equivalents | 95.8% | 232 | 118 | 108 | 92.00 | 78.00 |
Net PPE | 4.5% | 105 | 101 | 101 | 103 | 101 |
Liabilities | 8.0% | 164 | 152 | 138 | 149 | 156 |
Current Liabilities | 15.4% | 91.00 | 79.00 | 64.00 | 77.00 | 89.00 |
Shareholder's Equity | 26.9% | 500 | 394 | 473 | 552 | 622 |
Retained Earnings | -7.2% | -1,568 | -1,463 | -1,363 | -1,264 | -1,172 |
Additional Paid-In Capital | 11.3% | 2,069 | 1,859 | 1,839 | 1,818 | 1,795 |
Shares Outstanding | 19.0% | 188 | 158 | 158 | 157 | 157 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -8.9% | -292 | -268 | -262 | -239 | -227 |
Share Based Compensation | 0.5% | 84.00 | 84.00 | 83.00 | 75.00 | 70.00 |
Cashflow From Investing | -21.2% | 256 | 325 | 264 | 9.00 | 0.00 |
Cashflow From Financing | 5004.7% | 190 | 4.00 | 24.00 | 190 | 239 |
100%
90.8%
79.2%
Y-axis is the maximum loss one would have experienced if Iovance Biotherapeutics was unfortunately bought at previous high price.
-0.4%
3.4%
-19.5%
-37.6%
FIve years rolling returns for Iovance Biotherapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -69.97 | -1,093,090 | 273,907 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 11.34 | -76,000 | 219,000 | -% |
2023-02-28 | Voya Investment Management LLC | unchanged | - | -618,494 | 1,239,510 | -% |
2023-02-24 | NATIXIS | new | - | 6,646 | 6,646 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | sold off | -100 | -821,000 | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | -5,987 | 12,013 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -11.51 | -273,000 | 361,000 | -% |
2023-02-16 | CHARTWELL INVESTMENT PARTNERS, LLC | sold off | -100 | -447,000 | - | -% |
2023-02-15 | ATLAS CAPITAL ADVISORS LLC | sold off | -100 | -9,101 | - | -% |
2023-02-15 | JANE STREET GROUP, LLC | added | 67.58 | 68,262 | 651,262 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 17, 2023 | point72 asset management, l.p. | 4.6% | 7,347,600 | SC 13G | |
Feb 14, 2023 | avoro capital advisors llc | 4.4% | 7,020,000 | SC 13G/A | |
Feb 14, 2023 | perceptive advisors llc | 6.3% | 9,971,780 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.16% | 14,463,082 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 0.27% | 421,610 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 7.7% | 12,076,276 | SC 13G | |
Feb 02, 2023 | state street corp | 9.32% | 14,715,475 | SC 13G | |
Jan 13, 2023 | quogue capital llc | 12.52% | 2e+07 | SC 13D/A | |
Dec 30, 2022 | mhr fund management llc | 5.8% | 10,511,920 | SC 13G | |
Feb 24, 2022 | blackrock inc. | 4.7% | 7,408,505 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 10, 2023 | 8-K | Current Report | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Feb 28, 2023 | 10-K | Annual Report | |
Feb 28, 2023 | 8-K | Current Report | |
Feb 17, 2023 | SC 13G | Major Ownership Report | |
Feb 14, 2023 | SC 13G/A | Major Ownership Report | |
Feb 14, 2023 | SC 13G/A | Major Ownership Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-01-17 | BILINSKY IGOR | sold (taxes) | -30,034 | 6.43 | -4,671 | chief operating officer |
2023-01-17 | BILINSKY IGOR | acquired | - | - | 11,248 | chief operating officer |
2023-01-17 | Vogt Frederick G | acquired | - | - | 83,325 | interim ceo & general counsel |
2023-01-17 | GRAF FINCKENSTEIN FRIEDRICH | sold (taxes) | -30,079 | 6.43 | -4,678 | chief medical officer |
2023-01-17 | GRAF FINCKENSTEIN FRIEDRICH | acquired | - | - | 11,248 | chief medical officer |
2023-01-17 | Vogt Frederick G | sold (taxes) | -234,316 | 6.43 | -36,441 | interim ceo & general counsel |
2023-01-03 | BILINSKY IGOR | sold (taxes) | -64,478 | 6.11 | -10,553 | chief operating officer |
2023-01-03 | BILINSKY IGOR | acquired | - | - | 18,850 | chief operating officer |
2023-01-03 | Bellemin Jean-Marc | acquired | - | - | 18,850 | chief financial officer |
2023-01-03 | Bellemin Jean-Marc | sold (taxes) | -64,478 | 6.11 | -10,553 | chief financial officer |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Costs and expenses | |||
Research and development | $ 294,781 | $ 259,039 | $ 201,727 |
General and administrative | 104,097 | 83,664 | 60,210 |
Total costs and expenses | 398,878 | 342,703 | 261,937 |
Loss from operations | (398,878) | (342,703) | (261,937) |
Other income | |||
Interest income, net | 2,985 | 451 | 2,356 |
Net Loss | $ (395,893) | $ (342,252) | $ (259,581) |
Net Loss Per Share of Common Stock, Basic | $ (2.49) | $ (2.23) | $ (1.88) |
Net Loss Per Share of Common Stock, Diluted | $ (2.49) | $ (2.23) | $ (1.88) |
Weighted Average Shares of Common Stock Outstanding, Basic | 159,259 | 153,406 | 138,301 |
Weighted Average Shares of Common Stock Outstanding, Diluted | 159,259 | 153,406 | 138,301 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 231,731 | $ 78,229 |
Short-term investments | 240,114 | 426,181 |
Prepaid expenses and other assets | 7,271 | 3,546 |
Total Current Assets | 479,116 | 507,956 |
Property and equipment, net | 105,232 | 100,938 |
Operating lease right-of-use assets | 73,015 | 68,983 |
Long-term investments | 91,588 | |
Restricted cash | 6,430 | 6,084 |
Long-term assets | 189 | 1,784 |
Total Assets | 663,982 | 777,333 |
Current Liabilities | ||
Accounts payable | 26,603 | 27,377 |
Accrued expenses | 52,295 | 56,766 |
Operating lease liabilities | 12,587 | 5,057 |
Total Current Liabilities | 91,485 | 89,200 |
Non-Current Liabilities | ||
Operating lease liabilities - non-current | 71,859 | 65,474 |
Long-term note payable | 1,000 | 1,000 |
Total Non-Current Liabilities | 72,859 | 66,474 |
Total Liabilities | 164,344 | 155,674 |
Commitments and contingencies | ||
Stockholders' Equity | ||
Common stock, $0.000041666 par value; 300,000,000 shares authorized, 187,812,072 and 157,004,742 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively | 8 | 7 |
Accumulated other comprehensive loss | (902) | (601) |
Additional paid-in capital | 2,068,867 | 1,794,695 |
Accumulated deficit | (1,568,338) | (1,172,445) |
Total Stockholders' Equity | 499,638 | 621,659 |
Total Liabilities and Stockholders' Equity | 663,982 | 777,333 |
Series A Convertible Preferred Stock | ||
Stockholders' Equity | ||
Preferred stock, Value | 0 | 0 |
Series B Convertible Preferred Stock | ||
Stockholders' Equity | ||
Preferred stock, Value | $ 3 | $ 3 |